Clinical Trial

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single- arm, open-label, multicenter, phase II study to evaluate Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated mantle cell lymphoma
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-19; most recent amendment 2025-05-28.
Status change: Not Yet Recruiting → Recruiting 2025-05-28
Trial Details
NCT Number NCT06846489
Lead Sponsor Sun Yat-sen University
Conditions Mantle Cell Lymphoma (MCL)
Enrollment 50 participants
Start Date 2025-04-14
Primary Completion 2033-02-10 (estimated)
Study Completion 2033-02-20 (estimated)
Updated on ClinicalTrials.gov 2025-06-03